PL2523661T3 - Inhibitory NKCC do leczenia autyzmu - Google Patents
Inhibitory NKCC do leczenia autyzmuInfo
- Publication number
- PL2523661T3 PL2523661T3 PL11700533T PL11700533T PL2523661T3 PL 2523661 T3 PL2523661 T3 PL 2523661T3 PL 11700533 T PL11700533 T PL 11700533T PL 11700533 T PL11700533 T PL 11700533T PL 2523661 T3 PL2523661 T3 PL 2523661T3
- Authority
- PL
- Poland
- Prior art keywords
- autism
- treatment
- nkcc
- inhibitors
- nkcc inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10305047 | 2010-01-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2523661T3 true PL2523661T3 (pl) | 2017-09-29 |
Family
ID=42077420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11700533T PL2523661T3 (pl) | 2010-01-15 | 2011-01-13 | Inhibitory NKCC do leczenia autyzmu |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9415028B2 (pl) |
| EP (1) | EP2523661B1 (pl) |
| JP (1) | JP5914357B2 (pl) |
| CN (2) | CN102811716B (pl) |
| AU (1) | AU2011206574B2 (pl) |
| CA (1) | CA2786956C (pl) |
| CY (1) | CY1119167T1 (pl) |
| DK (1) | DK2523661T3 (pl) |
| ES (1) | ES2627914T3 (pl) |
| HR (1) | HRP20170836T1 (pl) |
| HU (1) | HUE034866T2 (pl) |
| LT (1) | LT2523661T (pl) |
| PL (1) | PL2523661T3 (pl) |
| PT (1) | PT2523661T (pl) |
| RS (1) | RS56080B1 (pl) |
| RU (1) | RU2583926C2 (pl) |
| SI (1) | SI2523661T1 (pl) |
| WO (1) | WO2011086126A1 (pl) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
| US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
| US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
| EP2318035B1 (en) | 2008-07-01 | 2019-06-12 | Curemark, Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
| US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
| EP2947100B1 (en) | 2009-01-06 | 2019-05-08 | Galenagen, LLC | Oral compositions for the treatment or the prevention of infections by E. Coli |
| US9107419B2 (en) | 2009-01-06 | 2015-08-18 | Curelon Llc | Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
| LT2523661T (lt) | 2010-01-15 | 2017-08-10 | INSERM (Institut National de la SantƩ et de la Recherche MƩdicale) | Nkcc inhibitoriai autizmo gydymui |
| US20120252894A1 (en) * | 2011-04-01 | 2012-10-04 | Giniatullin Rashid | Compounds for alleviating pain and stress in fetus and newborn |
| MX362974B (es) | 2011-04-21 | 2019-02-28 | Curemark Llc | Compuestos para el tratamiento de alteraciones neuropsiquiatricas. |
| BR112014016557A8 (pt) * | 2012-01-03 | 2017-07-04 | Curemark Llc | métodos de tratamento de sintomas comportamentais de distúrbios neurológicos e mentais |
| US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| US9719144B2 (en) | 2012-05-25 | 2017-08-01 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| CN105228652A (zh) * | 2013-02-21 | 2016-01-06 | 罗契斯特大学 | 评价全脑血管旁路径的废弃物清除功能的方法以及基于这种方法治疗神经退化性病症的方法 |
| WO2015091857A1 (en) | 2013-12-20 | 2015-06-25 | Fondazione Istituto Italiano Di Tecnologia | Modulators of intracellular chloride concentration for treating down syndrome |
| WO2016025778A1 (en) * | 2014-08-15 | 2016-02-18 | The Johns Hopkins University | Compositions and methods for treating refractory seizures |
| CN108243608A (zh) | 2015-05-22 | 2018-07-03 | 亚利桑那大学董事会 | 用于治疗自闭症谱系障碍及相关症状的方法 |
| US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| RU2633480C1 (ru) * | 2016-09-15 | 2017-10-12 | Александр Борисович Полетаев | Средство для стимуляции когнитивных функций при аутизме у детей |
| EP3388520A1 (en) * | 2017-04-11 | 2018-10-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for reducing the expression of nkcc1 in a subject in need thereof |
| EP3664823A4 (en) | 2017-08-07 | 2021-05-12 | Finch Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR MAINTAINING AND RESTORING A HEALTHY INTESTINAL BARRIER |
| CA3023014C (en) * | 2017-11-06 | 2023-09-26 | Stalicla Sa | Pharmaceutical composition for treatment of autism |
| JP2021525707A (ja) * | 2018-05-25 | 2021-09-27 | ザ チルドレンズ メディカル センター コーポレーション | 脊髄損傷を処置するための方法 |
| WO2020016160A1 (en) | 2018-07-16 | 2020-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat neurological diseases |
| CN110684775A (zh) * | 2019-07-01 | 2020-01-14 | 上海海洋大学 | 一种中华绒螯蟹nkcc基因及其克隆方法和表达分析方法 |
| CA3158575A1 (en) | 2019-10-31 | 2021-05-06 | Neurochlore | Liquid oral formulation of bumetanide |
| CN115023223A (zh) * | 2019-12-04 | 2022-09-06 | 雷斯乔制药有限责任公司 | 用于治疗口服利尿剂难治性水肿的方法和组合物 |
| EP3881842A1 (en) * | 2020-03-19 | 2021-09-22 | Stalicla S.A. | Compositions for the treatment of autism spectrum disorder |
| EP4175626A1 (en) * | 2020-07-01 | 2023-05-10 | Neuropro Therapeutics, Inc. | Novel pharmaceutical compositions |
| US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3985777A (en) | 1968-12-24 | 1976-10-12 | Lovens Kemiske Fabrik Produktionsaktieselskab | Sulphamyl-benzoic acid derivatives |
| US4247550A (en) | 1975-07-08 | 1981-01-27 | Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) | Compositions and methods for the treatment of hypertension or oedemas |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB2207129A (en) | 1987-07-13 | 1989-01-25 | Leo Pharm Prod Ltd | N-(1-carboxy-3-phenylpropyl)alanyl derivatives |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| EP0533838B1 (en) | 1990-06-11 | 1997-12-03 | NeXstar Pharmaceuticals, Inc. | Nucleic acid ligands |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| US8008283B2 (en) * | 1998-12-23 | 2011-08-30 | Neurotherapeutics Pharma, Inc. | Methods and compositions for the treatment of neuropsychiatric disorders |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US20070032410A1 (en) | 2000-01-11 | 2007-02-08 | Atossa Healthcare, Inc. | Compositions and methods for the treatment of psychiatric disorders |
| JP2003526367A (ja) | 2000-03-16 | 2003-09-09 | ジェネティカ インコーポレイテッド | Ｒｎａ干渉の方法とｒｎａ干渉組成物 |
| JP2007504136A (ja) | 2003-08-28 | 2007-03-01 | ニトロメッド インコーポレーティッド | ニトロソ化およびニトロシル化利尿化合物、組成物、ならびに使用方法 |
| JP2008535836A (ja) * | 2005-04-07 | 2008-09-04 | ニューロセラピューティクス ファーマ エルエルシー | 不安障害の治療のための方法および組成物 |
| US7763612B2 (en) | 2006-01-03 | 2010-07-27 | Algebra, Inc. | Therapeutic amine-arylsulfonamide conjugate compounds |
| EP2065038A1 (en) * | 2007-11-30 | 2009-06-03 | Pharnext | New therapeutic approaches for treating Charcot-Marie-Tooth disease |
| CL2009000294A1 (es) | 2008-02-08 | 2009-10-23 | Shlorion Pharma Inc | Compuestos derivados de heterociclos aril metilideno; composicion farmaceutica que los comprende; y uso en el tratamiento del dolor neuropatico e inflamacion. |
| AU2009225984A1 (en) | 2008-03-21 | 2009-09-24 | Chlorion Pharma, Inc. | Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain |
| US20120004225A1 (en) * | 2009-01-22 | 2012-01-05 | Neurotherapeutics Pharma, Inc. | Bumetanide, furosemide, piretanide, azosemide, and torsemide analogs, compositions and methods of use |
| WO2010132999A1 (en) | 2009-05-21 | 2010-11-25 | Chlorion Pharma, Inc. | Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics |
| LT2523661T (lt) | 2010-01-15 | 2017-08-10 | INSERM (Institut National de la SantƩ et de la Recherche MƩdicale) | Nkcc inhibitoriai autizmo gydymui |
| EP2598478A2 (en) | 2010-07-26 | 2013-06-05 | Neurotherapeutics Pharma, Inc. | Arylsulfonamide derivatives, compositions, and methods of use |
-
2011
- 2011-01-13 LT LTEP11700533.0T patent/LT2523661T/lt unknown
- 2011-01-13 CN CN201180014118.4A patent/CN102811716B/zh active Active
- 2011-01-13 DK DK11700533.0T patent/DK2523661T3/en active
- 2011-01-13 RS RS20170570A patent/RS56080B1/sr unknown
- 2011-01-13 US US13/522,372 patent/US9415028B2/en active Active
- 2011-01-13 WO PCT/EP2011/050394 patent/WO2011086126A1/en active Application Filing
- 2011-01-13 RU RU2012133067/15A patent/RU2583926C2/ru active
- 2011-01-13 EP EP11700533.0A patent/EP2523661B1/en active Active
- 2011-01-13 PT PT117005330T patent/PT2523661T/pt unknown
- 2011-01-13 AU AU2011206574A patent/AU2011206574B2/en active Active
- 2011-01-13 CA CA2786956A patent/CA2786956C/en active Active
- 2011-01-13 PL PL11700533T patent/PL2523661T3/pl unknown
- 2011-01-13 JP JP2012548435A patent/JP5914357B2/ja not_active Expired - Fee Related
- 2011-01-13 HU HUE11700533A patent/HUE034866T2/hu unknown
- 2011-01-13 ES ES11700533.0T patent/ES2627914T3/es active Active
- 2011-01-13 SI SI201131203T patent/SI2523661T1/sl unknown
- 2011-01-13 CN CN201710695535.9A patent/CN107595828A/zh active Pending
-
2013
- 2013-11-22 US US14/087,244 patent/US9592214B2/en active Active
-
2017
- 2017-05-31 HR HRP20170836TT patent/HRP20170836T1/hr unknown
- 2017-06-08 CY CY20171100608T patent/CY1119167T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2012133067A (ru) | 2014-02-20 |
| US20140080910A1 (en) | 2014-03-20 |
| SI2523661T1 (sl) | 2017-09-29 |
| CY1119167T1 (el) | 2018-02-14 |
| CA2786956C (en) | 2018-07-10 |
| JP2013517251A (ja) | 2013-05-16 |
| AU2011206574A1 (en) | 2012-08-09 |
| RU2583926C2 (ru) | 2016-05-10 |
| PT2523661T (pt) | 2017-06-21 |
| AU2011206574B2 (en) | 2015-01-22 |
| RS56080B1 (sr) | 2017-10-31 |
| US9415028B2 (en) | 2016-08-16 |
| ES2627914T3 (es) | 2017-08-01 |
| CA2786956A1 (en) | 2011-07-21 |
| EP2523661B1 (en) | 2017-05-10 |
| DK2523661T3 (en) | 2017-07-03 |
| US20130022622A1 (en) | 2013-01-24 |
| LT2523661T (lt) | 2017-08-10 |
| HRP20170836T1 (hr) | 2017-09-08 |
| US9592214B2 (en) | 2017-03-14 |
| WO2011086126A1 (en) | 2011-07-21 |
| HUE034866T2 (hu) | 2018-03-28 |
| JP5914357B2 (ja) | 2016-05-11 |
| CN107595828A (zh) | 2018-01-19 |
| CN102811716B (zh) | 2017-08-25 |
| EP2523661A1 (en) | 2012-11-21 |
| CN102811716A (zh) | 2012-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2523661T3 (pl) | Inhibitory NKCC do leczenia autyzmu | |
| IL225130A (en) | Devices for treating blood vessels defects | |
| ZA201304280B (en) | Treatment of jak2-mediated conditions | |
| EP2554175A4 (en) | COMPOSITION FOR THE TREATMENT OF A DESIRED PART | |
| EP2723384A4 (en) | TREATMENT OF PROTEINOPATHIES | |
| HK1198012A1 (zh) | 用於治療瘻的組合物 | |
| ZA201206456B (en) | Uses of dgati inhibitors | |
| SG2014014724A (en) | METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS | |
| PL3581199T3 (pl) | Sposoby leczenia lub zmniejszania panikulopatii obrzękowo- zwłóknieniowo-stwardnieniowej | |
| GB201018147D0 (en) | Method of treatment | |
| IL228719A0 (en) | parp inhibitors for the treatment of cipn | |
| IL256026A (en) | Treatment methods | |
| GB201003920D0 (en) | Method of treatment | |
| PL3081097T3 (pl) | Kompozycja do leczenia bezpłodności | |
| PT2460509T (pt) | Composição para tratamento de verrugas | |
| GB201020045D0 (en) | Method for the treatment of biogas | |
| EP2585103A4 (en) | METHOD OF TREATMENT | |
| GB201018149D0 (en) | Method of treatment | |
| GB201020015D0 (en) | Method of treatment | |
| EG26997A (en) | Tube for treatment of syrngomylia | |
| GB201010671D0 (en) | Compounds for treatment of inflammation | |
| GB201005495D0 (en) | Compounds for treatment of inflammation | |
| EP2532254A4 (en) | METHOD FOR PROCESSING A LACTO-N BIOSE-CONTAINED SOLUTION | |
| GB201005071D0 (en) | Method of treatment | |
| GB201003917D0 (en) | Method of treatment |